The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease.

Dave SinghArjun RaviKatie KaneTess SchmalbachDavid L Hava

Published in: British journal of clinical pharmacology (2018)

PUR0200 treatment caused bronchodilation in COPD patients that was similar in magnitude to that caused by tiotropium HH. This enabled a similar clinical effect on lung function to be achieved with PUR0200 using a lower metered dose of tiotropium compared with tiotropium HH.

Keyphrases

lung function
chronic obstructive pulmonary disease
end stage renal disease
cystic fibrosis
air pollution
newly diagnosed
ejection fraction
chronic kidney disease
drug delivery
prognostic factors
peritoneal dialysis
open label
patient reported outcomes
combination therapy
double blind